04:23 PM EDT, 09/17/2024 (MT Newswires) -- Structure Therapeutics ( GPCR ) said late Tuesday it has promoted Blai Coll to chief medical officer, replacing Mark Bach as part of a planned succession, effective Sept. 18.

Coll has been vice president of clinical development at Structure since 2022, the company said.

Additionally, Ashley Hall has been appointed to the newly created role of chief development officer, the clinical-stage biopharmaceutical company said. Prior to joining Structure, Hall served as chief development officer of Reneo Pharmaceuticals.